None have been approved by the Food and Drug Administration so far, though in 2019, Johnson & Johnson received FDA permission ...

Spravato (esketamine) is a nasal spray used for depression and was approved by the FDA in 2019. It is specifically for treatment-resistant depression, meaning depression symptoms that have not ...

Sanacora said that the Spravato efficacy data had to clear “a high bar” to win FDA approval. However, managing ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

Spravato (esketamine) is a prescription nasal spray that treats depression in adults. Learn about dosage, side effects, and more.

Spravato was previously approved by the FDA in 2019 for treatment-resistant depression, but it was required to be used with an oral antidepressant. The new FDA approval means people can use the ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.Johnson & Johnson's Spravato has been approved to treat a ...

The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.